Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of AKCEA APOCIII-LRx in familial chylomicronemia syndrome
MOH_2021-12-19_010491Phase 3Not yet recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Apr 2021
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary chylomicronemia (FCS) comparing AKCEA APOCIII-LRx with Placebo (2 arms). Primary endpoint: Percent change from baseline in fasting triglycerides. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
olezarsen
03
Conditions
primary chylomicronemia (FCS)
Beyond the preview
Go deeper on MOH_2021-12-19_010491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-12-19_010491.